| 0.2712 0.008 (3.08%) | 02-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.53 | 1-year : | 0.71 |
| Resists | First : | 0.45 | Second : | 0.61 |
| Pivot price | 0.25  |
|||
| Supports | First : | 0.2 | Second : | 0.17 |
| MAs | MA(5) : | 0.25  |
MA(20) : | 0.26 |
| MA(100) : | 0.52 |
MA(250) : | 0.58 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 44.6 |
| RSI | RSI(14): 37.2 |
|||
| 52-week | High : | 2.3 | Low : | 0.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PSTV ] has closed below upper band by 21.2%. Bollinger Bands are 75.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.27 - 0.27 | 0.27 - 0.27 |
| Low: | 0.25 - 0.25 | 0.25 - 0.25 |
| Close: | 0.27 - 0.27 | 0.27 - 0.27 |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Fri, 06 Feb 2026
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) - Yahoo Finance
Fri, 23 Jan 2026
H.C. Wainwright lowers Plus Therapeutics stock price target on equity offering - Investing.com
Thu, 22 Jan 2026
Plus Therapeutics plans CNS cancer test coverage for 150M US lives - Stock Titan
Thu, 22 Jan 2026
Plus Therapeutics To Provide Business Update Today As Radiotherapeutic Pipeline Advances - Nasdaq
Wed, 21 Jan 2026
Investors get Plus Therapeutics business update in Jan. 22 webcast - Stock Titan
Thu, 15 Jan 2026
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 178 (M) |
| Shares Float | 127 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 10.1 (%) |
| Shares Short | 11,360 (K) |
| Shares Short P.Month | 7,070 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | 0 % |
| Operating Margin | -320.9 % |
| Return on Assets (ttm) | -65.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -4.1 % |
| Gross Profit (p.s.) | -0.02 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | 6.78 |
| Price to Sales | 9.19 |
| Price to Cash Flow | -3.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|